In the September 10, 2022, the audience was treated to a wondrous MET exon 14 (METex14) skipping mutation discussion, including a real-world case discussion of a stage 4 non-small cell lung cancer (NSCLC) patient with METex14, mdm2 overexpression, and SMARCA4 deficiency.
MET inhibitor resistance was discussed in profound detail.
In addition, a MSI-high stage 4 prostate cancer patient was presented. Emphasis on immunotherapy and discussion of Pluvicto highlighted the discussion.
Novel clinical trial paradigms were discussed.
The Novartis pipeline was highlighted as their entire hematology/medical oncology drug development program was elucidated in a way few others are capable of.
NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD OR THE FOUR PRIOR RCIMTB TUMOR BOARDS. MSK, MD Anderson, Johns Hopkins, Mayo, etc., are not doing what is being done here, but they should be.
If you don't believe that, PLEASE SEE FOR YOURSELF.
This tumor board was hosted by:
Basem S. Goueli MD, PhD, MBA (co-host): CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel
Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.
It featured:
Ali Ucar: CEO and co-founder of CaresolutionsUSA
14 окт 2024
